David Jegou
Paris Descartes University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David Jegou.
Journal of Acquired Immune Deficiency Syndromes | 2008
Odile Launay; Sophie Grabar; Emmanuel Gordien; Corinne Desaint; David Jegou; Sébastien Abad; Pierre-Marie Girard; Linda Belarbi; Corinne Guérin; Jérôme Dimet; Virginie Williams; Anne Krivine; Dominique Salmon; Olivier Lortholary; David Rey
Background:The immunogenicity of vaccines, including vaccine against hepatitis A virus (HAV), is impaired in patients with HIV infection, requiring revised immunization regimens. Methods:We evaluated the immunological efficacy and safety of a 3-dose schedule of hepatitis A vaccine in HIV-infected adults. HAV-seronegative HIV-infected adults were randomized to receive either 3 doses of 1440 UI of hepatitis A vaccine (HAVRIX; GlaxoSmithKline, Marly le Roi, France) at weeks 0, 4, and 24 (46 patients) or 2 doses 24 weeks apart (49 patients). Results:At week 28, seroconversion, defined as an anti-HAV antibody ≥20 mIU/mL, occurred in 82.6% and 69.4% of patients in the 3-dose and the 2-dose group, respectively (P = 0.13, intent-to-treat analysis, missing data = nonresponder), and in 88.4% and 72.3% of patients in the 3-dose and the 2-dose group, respectively (P = 0.06, observed analysis). Only 37.9% of patients experienced seroconversion after 1 vaccine dose (intent-to-treat analysis). Anti-HAV antibody geometric mean titers were 323 and 132 mIU/mL in the 3-dose group and 138 and 67 mIU/mL in the 2-dose group, respectively, 28 (P = 0.03) and 72 weeks (P = 0.05) after the first vaccine dose. There were no serious adverse events associated with the vaccine. Multivariate analysis showed no treatment group effect but indicated that absence of tobacco smoking (odds ratio = 2.92, 95% confidence interval: 1.07 to 7.97; P = 0.04) was an independent predictor of response to HAV vaccine. Conclusions:In HIV-infected adults, immunogenicity of hepatitis A vaccine is poor. Three doses of vaccine were safe and increased antibody titers.
American Journal of Emergency Medicine | 2009
Frédéric Bloch; David Jegou; Jean-François Dhainaut; Anne-Sophie Rigaud; Joël Coste; Jean-Eric Lundy; Y.-E. Claessens
BACKGROUND Fall-related morbidity is a serious public health issue in older adults referred to emergency departments (EDs). Emergency physicians mostly focus on immediate injuries, whereas the specific assessment of functional consequences and opportunities for prevention remain scarce. The aim of this study was to determine the factors influencing 6-month independence. METHODS We used a prospective observational study at the ED of a tertiary teaching hospital over a 6-month period. Uni- and multivariate assessments of factors related to loss of independence were examined. RESULTS A total of 367 patients survived to 6 months, mean age was 86 years, and 79% were women. The population was initially healthy and independent. Because this independence reassured the medical staff, more than 42% percent were directly discharged home without any improvement of home facilities; only 63% had recovered their independence at the end of the follow-up. There were 111 patients were hospitalized for 30 days or more. Older patients, initial Katz score, and absence of immediate trauma consequences were associated with an increased risk for loss of independence. CONCLUSIONS Because prevention is an emerging role of ED, a multidisciplinary team should evaluate fallers and propose medical and environmental changes as required for those discharged after their ED visit.
Vaccine | 2008
Odile Launay; Sophie Grabar; Frédéric Bloch; Corinne Desaint; David Jegou; Christophe Lallemand; Robert Erickson; Pierre Lebon; Michael G. Tovey
A randomized double-blind placebo-controlled study was conducted to determine the effect of sublingual administration of IFNalpha on the immune response to influenza vaccination in elderly institutionalized individuals. Sublingual administration of 10 million IU of IFNalpha immediately prior to vaccination, reduced the geometric mean haemagglutination inhibitory (HAI) and IgG2 circulating antibody titers, and the secretory IgA (sIgA) response in saliva, to the New York strain of influenza A virus, 21 days post-vaccination, without detectable drug-related local or systemic toxicity. IFN treatment did not inhibit the immune response to the other components of the vaccine; the New Caledonia strain of influenza A virus, or the Jiangsu strain of influenza B virus. At the dose tested sublingual administration of IFNalpha reduces the immune response to influenza vaccination in elderly institutionalized individuals.
International Journal of Geriatric Psychiatry | 2011
Jocelyne de Rotrou; I. Cantegreil; Véronique Faucounau; Catherine Chausson; David Jegou; Sophie Grabar; Anne-Sophie Rigaud
Intensive Care Medicine | 2010
Y.-E. Claessens; Thierry Mathevon; G. Kierzek; Sophie Grabar; David Jegou; Eric Batard; Clarisse Loyer; Alain Davido; Pierre Hausfater; Hélène Robert; Leila Lavagna-Perez; Bruno Bernot; Patrick Plaisance; Christophe Leroy; Bertrand Renaud
Clinical Microbiology and Infection | 2010
Y.-E. Claessens; J. Schmidt; E. Batard; Sophie Grabar; David Jegou; P. Hausfater; G. Kierzek; Sylvie Guérin; J.-L. Pourriat; J. F. Dhainaut; C. Ginsburg
AIDS | 2010
Emmanuel Dulioust; Marianne Leruez-Ville; Juliette Guibert; Alessandra Fubini; David Jegou; Odile Launay; Philippe Sogni; Pierre Jouannet; Christine Rouzioux
European Journal of Epidemiology | 2009
Frédéric Bloch; David Jegou; Jean-François Dhainaut; Anne-Sophie Rigaud; Joël Coste; Jean-Eric Lundy; Y.-E. Claessens
Journal Européen des Urgences | 2008
Frédéric Bloch; David Jegou; J.-L. Pourriat; Anne-Sophie Rigaud; S. André; Jean-Eric Lundy; Y.-E. Claessens
Journal Européen des Urgences | 2007
Frédéric Bloch; Y.-E. Claessens; Jean-Eric Lundy; David Jegou; J.-F. Dhainaut